Nilutamide
Alternative Names: Anandron; Nilandron; RU 23908Latest Information Update: 07 Jan 2022
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antiandrogens; Antineoplastics; Imidazolidines; Nitrobenzenes; Small molecules
- Mechanism of Action Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 18 Jul 2016 Generic equivalent approved in US FDA for Prostate cancer (Metastatic disease)
- 05 Apr 2013 Discontinued - Phase-III for Prostate cancer (metastatic disease) in Peru (PO) before 2013
- 05 Apr 2013 No development reported - Clinical-Phase-Unknown for Prostate cancer (metastatic disease) in Japan (PO)